International Immunology, Vol. 11, No. 7, 1059-1064,
July 1999
© 1999 Japanese Society for Immunology
BALB/c.CBA/N mice carrying the defective Btkxid gene are resistant to pristane-induced plasmacytomagenesis
Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Building 37, Room 2B04, 37 Convent Drive, MSC4255, Bethesda, MD 20892, USA
1 PerImmune, Inc., 1330 Piccard Drive, Rockville, MD 20850-4390, USA
2 Office of Research Services, Office of the Director, National Institutes of Health, Bethesda, MD 20892-5590, USA
3 National Institute of Aging, National Institutes of Health, 4940 Eastern Avenue, MS28, Baltimore, MD 21224, USA
Correspondence to: M. Potter
The X-chromosome from the CBA/N mouse which carries the defective Bruton's tyrosine kinase (Btk) allele (Xxid) has been introgressively backcrossed onto the plasmacytoma (PCT) induction-susceptible BALB/cAN. Inbred BALB/c.CBA/N-xid/xid (C.CBA/N) mice raised and maintained in our conventional colony were given three 0.5 ml injections of pristane and were highly refractory to PCT induction. Only one PCT was found among 59 mice followed for 
300 days. Twenty mice were examined at day 200 for foci of plasma cells in the oil granuloma. Ten mice had small foci of plasma cells, most of which were plasmacytotic, embedded in the inflammatory oil granuloma. In one there were multiple foci, but most of the mice had only one or two foci. F1 hybrid XxidY males derived from CBA/N females crossed to BALB/cAnPt were also resistant to PCT induction, while heterozygous and homozygous XY males were susceptible. C.CBA/N mice can develop extensive mucosal plasma cells as well as plasma cell accumulations in oil granuloma tissue, but the precursors of these plasma cells do not give rise to PCT in genetically susceptible hosts. The failure of C.CBA/N mice to develop PCT is probably due to the elimination of B cell clones that can be perpetuated by repeated exposure to thymus-independent type 2 antigens.
Keywords: B-1 lymphocytes, Bruton's tyrosine kinase, CBA/N, plasmacytoma, pristane, TI-2 antigens, xid
Transmitting editor: J. F. Kearney
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-F. Qi, J. X. Zhou, C. H. Lee, Z. Naghashfar, S. Xiang, A. L. Kovalchuk, T. N. Fredrickson, J. W. Hartley, D. C. Roopenian, W. F. Davidson, et al. Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells Cancer Res., March 15, 2007; 67(6): 2439 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Felix, S. Gerstmeier, A. Kyriakopoulos, O. M. Z. Howard, H.-F. Dong, M. Eckhaus, D. Behne, G. W. Bornkamm, and S. Janz Selenium Deficiency Abrogates Inflammation-Dependent Plasma Cell Tumors in Mice Cancer Res., April 15, 2004; 64(8): 2910 - 2917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Kovalchuk, J. S. Kim, S. S. Park, A. E. Coleman, J. M. Ward, H. C. Morse III, T. Kishimoto, M. Potter, and S. Janz IL-6 transgenic mouse model for extraosseous plasmacytoma PNAS, January 17, 2002; (2002) 22643999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kovalchuk, J. S. Kim, S. S. Park, A. E. Coleman, J. M. Ward, H. C. Morse III, T. Kishimoto, M. Potter, and S. Janz IL-6 transgenic mouse model for extraosseous plasmacytoma PNAS, February 5, 2002; 99(3): 1509 - 1514. [Abstract] [Full Text] [PDF]
|
|